STAT

AUGUST 8, 2024

Chamber of Commerce lawsuit challenging Democrats’ drug pricing law. The decision is yet another loss for the pharmaceutical industry and its allies, which have filed lawsuits across the country arguing that the Inflation Reduction Act, which created a drug price negotiation program in Medicare , is unconstitutional.

Drug Pricing 321

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 321

STAT

OCTOBER 21, 2024

WASHINGTON — Most executives at pharmaceutical companies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. 30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drug pricing reform in decades in 2022. 

Drug Pricing 362

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 362

STAT

DECEMBER 23, 2024

WASHINGTON — Three large pharmaceutical companies left the brand-drug lobby PhRMA after the passage of Democrats’ drug pricing law in 2022. Following the exits, the organization collected $100 million less in annual membership dues, new tax filings show.

Drug Pricing 299

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 299

STAT

OCTOBER 2, 2023

… A federal court judge allowed the new Medicare drug price negotiation program to proceed while the court deliberates whether it is constitutional , STAT reports. Meanwhile, Novo Nordisk became the latest pharmaceutical company to file a lawsuit against the Medicare drug price negotiation program , Bloomberg Law tells us. The

Drug Pricing 260

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 260

STAT

DECEMBER 6, 2023

The departure is a blow to the trade group, which represents members ranging from small biotech startups to massive pharmaceutical companies. Pfizer is a prominent member of PhRMA, the lobbying group for brand-name drug companies, and its chief executive officer, Albert Bourla, is its board treasurer.

Drug Pricing 266

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 266

STAT

DECEMBER 7, 2023

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

Drug Pricing 313

Drug Pricing Compounding Pharmaceutical Companies Pharmaceutical Companies 313

STAT

AUGUST 8, 2024

This is Part 3 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Discovering a new drug is a big win for a pharmaceutical company, but selling it for lots of money with no competition? The cherry on top. Read the rest…

Drug Pricing 319

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 319

STAT

APRIL 22, 2025

Four months ago, a small pharmaceuticals company bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150%. But the company, Eton Pharmaceuticals, argues there is no other way to keep its treatment on the market and make a profit.

Pharmaceutical Companies 247

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 247

STAT

DECEMBER 19, 2024

Access to cheaper alternatives and low enrollment prompted the company to remove the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from its patent assistance program next month, according to an Oct. 8 letter that announced the move and that has not been widely reported.

Pharmaceutical Companies 327

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 327

STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

Biosimilars 363

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 363

STAT

NOVEMBER 1, 2023

A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising drug prices to controversial heights — agreed to pay up to $50 million to settle allegations of purposely underpaying Medicaid rebates.

Drug Pricing 334

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 334

STAT

JANUARY 26, 2023

In her latest bid to address prescription drug prices, U.S. Federal Trade Commission to “closely scrutinize” two pending pharmaceutical company mergers over concerns that “rampant consolidation” will drive up costs for consumers. Elizabeth Warren (D-Mass.) is urging the U.S.

Drug Pricing 253

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 253

STAT

MARCH 22, 2023

In the face of rising drug prices, health plan sponsors have quietly used a clever, but questionable tactic over the past few years to deflect costs. And now, some pharmaceutical companies are pushing back.

Drug Pricing 246

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 246

STAT

JUNE 21, 2023

“They talk in such generalities on this subject that it’s difficult for me to tell where they’re coming from,” he said at a STAT event Wednesday, speaking about top GOP senators’ approach to reforming the drug pricing middlemen who negotiate between pharmaceutical companies and insurers.

Drug Pricing 253

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 253

STAT

MARCH 28, 2023

drug crisis has accelerated, the pharmaceutical industry has jumped into action — particularly when it comes to naloxone, the drug used to reverse opioid overdoses , STAT reports. … As the U.S.

Drug Pricing 246

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 246

STAT

JULY 6, 2023

But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices.

Drug Pricing 246

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 246

STAT

MARCH 17, 2025

In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.

Biosimilars 184

Biosimilars Hospitals Pharmaceutical Companies Pharmaceutical Companies 184

Pharmaceutical Technology

NOVEMBER 22, 2023

A US senate committee scheduled a hearing on prescription drug pricing with major pharmaceutical companies.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 98

Drug Patent Watch

JANUARY 8, 2025

Understanding the Basics of Drug Patents Before diving into the nuances of patent strategy, it’s crucial to grasp the fundamentals. Drug patents are a form of intellectual property protection that grants pharmaceutical companies exclusive rights to manufacture, sell, and profit from their innovations for a set period.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Documentation 52

Express Pharma

NOVEMBER 28, 2024

Global pharmaceutical companies have played a pivotal role in transforming the healthcare sector in India. Approximately 70 per cent of global pharmaceutical companies are expected to achieve annual growth of over 10 per cent in India over the next five years.

Pharmaceutical Companies 106

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 106

STAT

OCTOBER 7, 2022

… The drug-pricing law will still penalize pharmaceutical companies if they hike prices on medicines for patients who have private insurance, STAT says. The penalties may factor into decisions for pricing medicines as the new law begins to take effect. Enjoy, and see you soon.

Drug Pricing 240

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 240

STAT

AUGUST 9, 2024

Chamber of Commerce lawsuit challenging the Medicare Drug Price Negotiation Program established through the Inflation Reduction Act, with a judge finding that several plaintiffs in the suit lacked standing , STAT reports. Or you could simply hide indoors and binge-watch something on the telly. Well, whatever you do, have a grand time.

Drug Pricing 253

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 253

STAT

FEBRUARY 15, 2024

For several years , some of the world’s largest pharmaceutical companies that participate in a U.S. drug discount program overcharged the federal government and numerous hospitals by hundreds of millions of dollars, according to claims made in a recently unsealed lawsuit. and their number has grown over the years.

Hospitals 330

Hospitals Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 330

STAT

JULY 22, 2024

The report , which was released in March but received little if any public attention, examined drug spending between 2016 and 2021 within the health plan that covers more than 200,000 unionized mail carriers and post office workers, as well as retirees.

Pharmaceutical Companies 363

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 363

STAT

SEPTEMBER 24, 2024

In the latest slap at a pharmaceutical company by a local government, the city of Baltimore has filed a lawsuit accusing Biogen of striking an “unlawful” scheme with the largest pharmacy benefit managers to block generic competition of a best-selling multiple sclerosis treatment.

Pharmaceutical Companies 359

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 359

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports.

Vaccines 244

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 244

STAT

OCTOBER 17, 2023

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

Pharmaceutical Companies 354

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 354

STAT

OCTOBER 10, 2024

At the same time, Teva steadily raised the price of its drug by thousands of dollars.

Pharmaceutical Companies 320

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 320

STAT

OCTOBER 2, 2024

In reality, the arrangements actually resemble private-label distribution, but the lawmakers worry these agreements could cause consumers to pay higher prices.

Labelling 308

Labelling Biosimilars Pharmaceutical Companies Pharmaceutical Companies 308

STAT

JUNE 17, 2024

Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceutical companies to delay the arrival of lower-cost generic medicines in the marketplace. In a bid to prevent the patent system from being abused, the U.S.

Generic Medicine 313

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 313

STAT

SEPTEMBER 19, 2024

Sometimes, a delay is caused by a patent review, so the PTO will compensate a pharmaceutical company by extending the life of the patent by the number of days caused by the delay. Conversely, if a company was slow to respond to requests, the time is subtracted from the patent life.

Pharmaceutical Companies 308

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 308

STAT

MARCH 21, 2024

As more states create dedicated boards to cap the costs of medicines, some drugmakers and their allies are pushing back with a controversial tactic — lobbying for legislation to set exemptions for so-called orphan drugs, which are used to combat rare diseases that afflict relatively small groups of patients.

Pharmaceutical Companies 338

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 338

STAT

DECEMBER 4, 2024

Patent & Trademark Office has withdrawn a controversial proposal that was designed to prevent pharmaceutical companies from abusing the patent system. In an unexpected move, the U.S.

Generic Medicine 289

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 289

BioPharma Dive

JUNE 15, 2023

Lobbying group PhRMA does not expect any near-term changes to the IRA’s drug pricing provisions, but is attempting to lay groundwork for future changes.

Drug Pricing 60

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 60

The Guardian - Pharmaceutical Industry

JUNE 9, 2024

With the heavy encouragement of pharmaceutical companies, the blame for such shortfalls often falls on the National Institute for Health and Care Excellence (Nice), the public body that advises the NHS on whether medicines represent value for money.

Drug Pricing 95

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 95

STAT

JANUARY 6, 2023

The Food and Drug Administration on Friday approved a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. Read the rest…

Pharmaceutical Companies 246

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 246

STAT

OCTOBER 10, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.

Packaging 289

Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 289